GRI:NSD-GRI Bio Inc. (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.827

Change

+0.21 (+34.67)%

Market Cap

N/A

Volume

0.01B

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-30 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+4.72 (+1.00%)

USD 121.32B
REGN Regeneron Pharmaceuticals Inc

-4.54 (-0.49%)

USD 103.77B
ALNY Alnylam Pharmaceuticals Inc

-3.20 (-1.12%)

USD 36.83B
ARGX argenx NV ADR

-1.17 (-0.21%)

USD 33.21B
BGNE BeiGene Ltd

-10.54 (-4.87%)

USD 24.57B
MRNA Moderna Inc

-0.50 (-0.91%)

USD 20.52B
RPRX Royalty Pharma Plc

+0.04 (+0.15%)

USD 16.47B
UTHR United Therapeutics Corporatio..

+8.60 (+2.44%)

USD 15.69B
SMMT Summit Therapeutics PLC

-3.18 (-14.57%)

USD 15.13B
PCVX Vaxcyte Inc

+0.55 (+0.52%)

USD 13.95B

ETFs Containing GRI

UKPH:XETRA iShares UK Property UCITS.. 3.23 % 0.00 %

+0.01 (+0.20%)

N/A
UKRE:LSE iShares MSCI Target UK Re.. 2.48 % 0.00 %

+0.05 (+0.20%)

USD 0.12B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 114.81% 64% D 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 114.81% 64% D 81% B-
Trailing 12 Months  
Capital Gain -31.08% 20% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -31.08% 20% F 21% F
Trailing 5 Years  
Capital Gain -98.32% 2% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -98.32% 2% F 1% F
Average Annual (5 Year Horizon)  
Capital Gain -31.41% 13% F 7% C-
Dividend Return -31.41% 13% F 7% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 45.54% 67% D+ 41% F
Risk Adjusted Return -68.97% 16% F 11% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector